Thymosin Alpha-1, in brief. Thymosin alpha-1 is a small peptide, 28 amino acids long, first purified from calf thymus, the organ where T cells mature. Its job is to act as an alarm amplifier for the immune system. It helps dendritic cells, the cells that spot invaders and show them to T cells, mature and send out the signal molecule IL-12, and that pushes T cells toward the type of response that clears viruses, fungi and tumor cells. It does not kill microbes itself; it changes how strongly immune cells react to them. In mice, that showed up as more animals surviving fungal infection and endotoxin shock, and as fewer and smaller melanoma tumors. A synthetic version, thymalfasin, is a prescription drug in some countries but is not approved by the FDA. NextGenPeps supplies Thymosin Alpha-1 as a 10 mg lyophilized research peptide, tested by independent labs, for laboratory use only.
What does Thymosin Alpha-1 do?
It turns up immune cell activity rather than acting on a pathogen or a tumor directly. Its effects run mostly through dendritic cells and T cells, which is why it is studied wherever immune responses are too weak, such as infection, sepsis and cancer models.[2,3]
Dendritic cells. It helps them mature and raises their IL-12 output, the signal that tells T cells what kind of response to mount.[3]
T cells. It shifts the response toward Th1, the arm that handles intracellular microbes, fungi and tumor cells.[3]
Whole animals. In mice it increased survival in fungal infection and endotoxin sepsis models and reduced melanoma growth and spread.[3,4,5,6]
Thymosin alpha-1 is not related to thymosin beta-4 (TB-500) despite the shared name; the two are different molecules with different jobs, covered below.
How does Thymosin Alpha-1 work?
It works through the receptors immune cells use to recognize microbes, so it makes those cells react as if a threat were present, more strongly.
In mouse dendritic cells exposed to the mold Aspergillus fumigatus, thymosin alpha-1 drove maturation and IL-12 production through Toll-like receptors and the adaptor protein MyD88, with downstream activation of the p38 MAPK and NF-kB pathways. In the same study it activated Th1-dependent antifungal immunity and sped up recovery of myeloid cells.[3] In plasmacytoid dendritic cells, the expansion it causes depends on TLR9 and type I interferon signaling.[2] Its exact receptor target is still not pinned down.

Figure 1. How thymosin alpha-1 signals in dendritic cells. Simplified pathway from mouse dendritic cell work, Romani et al. 2004, with the plasmacytoid dendritic cell branch from Costantini et al. 2019.[2,3]
What did Thymosin Alpha-1 do in animal studies?
In mice it kept more animals alive through severe infection and endotoxin shock, and it slowed melanoma. The results come from a handful of studies, often small, and some from authors with declared industry links.
Endotoxin sepsis. C57BL/6J mice were given bacterial endotoxin (LPS, 10 mg/kg) to induce sepsis, 18 per group. Every untreated septic mouse was dead by 24 hours. At 72 hours, 55.6% of the thymosin alpha-1 group were alive, against 27.8% with hydrocortisone and 83.3% with both together.[6]

Figure 2. Survival after endotoxin-induced sepsis in mice. Percent of mice alive 72 hours after LPS, 18 per group, from Zhang et al. 2015.[6] One study in one sepsis model.
Fungal infection. In mice infected intravenously with Candida albicans, thymosin alpha-1 given before infection protected against lethal infection, and it reversed the extra susceptibility caused by the immune-suppressing drug cyclophosphamide. Given only after infection, it gave no protection at any dose tested.[4] In mice that had received bone marrow transplants, a model highly susceptible to aspergillosis, it protected against Aspergillus infection.[3]
Melanoma. In a mouse B16 melanoma lung metastasis model, thymosin alpha-1 alone reduced metastases by 32%. In a B16 tumor growth model it reduced tumor growth by 34% to 46%, depending on the dose. In a cecal ligation and puncture sepsis model run in the same report, survival and bacterial load only trended in its favor.[5]

Figure 3. Thymosin alpha-1 in mouse melanoma models. Reductions compared with vehicle, from King and Tuthill 2015, described by the authors as pilot studies.[5]
Thymosin Alpha-1 in clinical trials
Clinical results are mixed: an early sepsis trial suggested a benefit, and a larger placebo-controlled trial did not confirm it.
In the ETASS severe sepsis trial (Critical Care 2013, 361 participants, single-blind with no placebo), 28-day mortality was 26.0% with thymosin alpha-1 and 35.0% in the control group, a relative risk of 0.74 (95% CI 0.54 to 1.02).[7] The later TESTS trial (BMJ 2025) was double-blind and placebo controlled across 22 centers, with 1,089 participants in the main analysis. 28-day mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo (hazard ratio 0.99, 95% CI 0.77 to 1.27), and the authors found no clear evidence of a mortality benefit.[8]
Thymosin Alpha-1 vs Thymosin Beta-4 (TB-500)
They share a name because both were first found in thymus extracts, but they are unrelated molecules that are studied for different things.
Size. Thymosin alpha-1 is 28 amino acids (3,108 Da); thymosin beta-4 is 43 amino acids (about 4,963 Da).[1,9]
Main role. Thymosin alpha-1 is an immune signal acting on dendritic cells and T cells; thymosin beta-4 binds actin inside cells and is studied for cell migration and tissue repair.[2,9]
Research focus. Thymosin alpha-1: infection, sepsis, vaccine response and tumor immunity. Thymosin beta-4: wound healing and new blood vessel growth.[9]
Status. Thymalfasin is a prescription drug in some countries outside the US. Thymosin beta-4 is not an FDA-approved drug and is on the World Anti-Doping Agency Prohibited List.
NextGenPeps carries both; see the TB-500 page for thymosin beta-4. KPV and LL-37 are other immune-related peptides on this store.
What is Thymosin Alpha-1 made of?
It is a single short chain of 28 amino acids with an acetyl group capping the first one, and no disulfide bonds or sugars.
Goldstein and colleagues isolated and sequenced it from calf thymus in 1977, describing a heat-stable, highly acidic peptide of 28 residues.[1] Its N-terminal serine is acetylated.[2] The sequence is Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH, molecular formula C129H215N33O55, with a molecular weight of about 3,108 Da.[2] Many glutamate and aspartate residues make it strongly acidic. Thymalfasin is the synthetic version of this same sequence.
Thymosin Alpha-1 at a glance
Compound: Thymosin alpha-1 (thymalfasin, Ta1)
Class: Acetylated thymic peptide; immune modulator acting through Toll-like receptor signaling in dendritic cells
Sequence: Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN-OH (28 residues)[1]
Molecular formula: C129H215N33O55
Molecular weight: About 3,108 Da[2]
Strength: 10 mg per vial
Identity and purity: Identity by LC-MS/MS and purity by RP-HPLC at 214 nm; 99.58% on the current lot (September 25, 2026). The earlier January 2026 lot recorded 99.62%. Both certificates are in the COA library
Endotoxin: Under 0.05 EU/ml on the current lot, per USP <85>. The January 2026 lot was not endotoxin tested
Appearance: White lyophilized powder, sealed vial
Reconstitution: Sterile or bacteriostatic water
Regulatory status: Not FDA approved; thymalfasin is a prescription drug in some countries outside the US[10,11]
Is Thymosin Alpha-1 FDA approved?
No. Thymosin alpha-1 is not an FDA-approved drug in the United States.
Outside the US, the synthetic form thymalfasin has been licensed as a prescription drug in some countries; Singapore, for example, granted it marketing approval for chronic hepatitis B, as reported in 1997.[10] The FDA lists thymosin alpha-1 among bulk substances that were nominated for pharmacy compounding and then withdrawn (formerly Category 2), noting possible immunogenicity, complexity around peptide impurities and characterisation, and limited safety information. This concerns compounding only and does not make it an approved drug.[11] NextGenPeps sells it strictly for laboratory research.
What is Thymosin Alpha-1 used to study?
Researchers use it as a defined tool for boosting dendritic cell and T-cell responses in models where those responses are weak.
Infection models. Fungal, bacterial and viral infection in normal and immune-suppressed animals, including Candida and Aspergillus.[3,4,12]
Sepsis. Endotoxin and cecal ligation and puncture models, where it is studied for survival and immune recovery.[5,6]
Tumor immunology. Melanoma metastasis and tumor growth, alone and with checkpoint antibodies such as anti-PD-1.[2,5]
Dendritic cell and Toll-like receptor signaling. How a peptide shifts IL-12 output and Th1 polarization.[3]
Vaccine response. Its potential as an adjuvant that links innate and adaptive immunity.[3,12]
Buying Thymosin Alpha-1 for research: what each vial includes
Each lot is checked for identity, purity and endotoxin by independent labs. The current lot was tested on September 25, 2026: identity by LC-MS/MS, purity by RP-HPLC at 214 nm (99.58%), content by HPLC quantitation, and endotoxin under 0.05 EU/ml per USP <85>. Every certificate is published in the NextGenPeps COA library.
Verified identity, purity and endotoxin. 99.58% purity and under 0.05 EU/ml endotoxin on the current lot.
US-based fulfillment. Orders ship within 24 hours from the United States, with free US shipping on orders over $150.
Research use only. Thymosin Alpha-1 is sold strictly for in vitro and approved animal research. It is not for human or veterinary use and is not sold as a drug, supplement or diagnostic.
Thymosin Alpha-1 handling, storage and analytical notes
Format. Supplied as lyophilized powder in a sealed 10 mg vial and reconstituted with sterile or bacteriostatic water. No dosing instructions are supplied, and none should be taken from the studies above.
Storage. Keep the sealed vial at 2 to 8 °C, or -20 °C for longer holding, protected from light and moisture. After reconstitution hold the solution at 2 to 8 °C and avoid repeated freeze-thaw cycles.
Handling. Confirm concentration against the lot's measured content value rather than the label mass alone, and note the lot number in experimental records so results can be traced to its certificate.
Naming. Thymosin alpha-1, Ta1, TA-1 and thymalfasin all refer to the same 28-residue peptide. It is cut from a larger precursor, prothymosin alpha, and is distinct from thymosin beta-4 (TB-500) and from thymic extracts such as thymosin fraction 5.
What is not established about Thymosin Alpha-1
A mortality benefit in sepsis. The larger, placebo-controlled TESTS trial found no clear reduction in 28-day mortality, unlike the earlier single-blind ETASS trial.[7,8]
Its direct receptor. Toll-like receptor signaling is involved, but a single defined binding target has not been established.[2,3]
How broadly animal results hold. Many animal studies are small and test a single model, and some come from authors with declared links to the drug's developer.[5,6]
Research-grade equivalence. Research peptide is not manufactured to pharmaceutical standards, so results from licensed thymalfasin do not automatically transfer.
Research Use Only. The statements made within this website have not been evaluated by the US Food and Drug Administration. These materials are not intended to diagnose, treat, cure or prevent any disease and are not intended for human or veterinary use. Studies described on this page are reported for scientific context and are not guidance of any kind.